Andrew J Kassianos
Overview
Explore the profile of Andrew J Kassianos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urquhart A, Glass C, Humphries T, Kassianos A, Vesey D, Wood S, et al.
Per Med
. 2025 Mar;
:1-9.
PMID: 40029183
Background: Metastatic renal cell carcinoma (RCC) is often treated with a combination of immunotherapy and tyrosine kinase inhibitors (TKIs). Patient-derived RCC cells were cultured and inter-individual differences to treatment with...
2.
Wise A, Krisnadevi I, Bruell S, Lee H, Bhuvan T, Kassianos A, et al.
Kidney Int Rep
. 2025 Feb;
10(2):535-548.
PMID: 39990892
Introduction: Fabry disease (FD) results from pathogenic variants, leading to a deficiency in lysosomal α-galactosidase A (α-Gal A) and accumulation of the sphingolipid globotriaosylceramide (Gb3). This leads to severe renal...
3.
Humphries T, Lee S, Urquhart A, Vesey D, Micallef A, Winterford C, et al.
Physiol Rep
. 2025 Feb;
13(4):e70249.
PMID: 39957082
Tubulointerstitial fibrosis is a characteristic hallmark of chronic kidney disease (CKD). Metabolic perturbations in cellular energy metabolism contribute to the pathogenesis of CKD, but the chemical contributors remain unclear. The...
4.
Giuliani K, Nag P, Adams B, Wang X, Hong S, Grivei A, et al.
Cell Death Dis
. 2025 Jan;
16(1):61.
PMID: 39890773
Hypoxia and interleukin (IL)-1β are independent mediators of tubulointerstitial fibrosis, the histological hallmark of chronic kidney disease (CKD). Here, we examine how hypoxia and IL-1β act in synergy to augment...
5.
Giuliani K, Adams B, Healy H, Kassianos A
Front Cell Dev Biol
. 2024 Nov;
12:1497460.
PMID: 39544363
Chronic kidney disease (CKD) is the progressive loss of kidney function/structure over a period of at least 3 months. It is characterised histologically by the triad of cell loss, inflammation...
6.
Wang X, Kim C, Adams B, Wilkinson R, Hill M, Shah A, et al.
Redox Biol
. 2024 Jan;
70:103042.
PMID: 38244399
Hypoxia is the key pathobiological trigger of tubular oxidative stress and cell death that drives the transition of acute kidney injury (AKI) to chronic kidney disease (CKD). The mitochondrial-rich proximal...
7.
Raghubar A, Matigian N, Crawford J, Francis L, Ellis R, Healy H, et al.
NPJ Precis Oncol
. 2023 Sep;
7(1):88.
PMID: 37696903
Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the...
8.
Raghubar A, Crawford J, Jones K, Lam P, Andersen S, Matigian N, et al.
Methods Mol Biol
. 2023 Jul;
2664:233-282.
PMID: 37423994
Unlike bulk and single-cell/single-nuclei RNA sequencing methods, spatial transcriptome sequencing (ST-seq) resolves transcriptome expression within the spatial context of intact tissue. This is achieved by integrating histology with RNA sequencing....
9.
Raghubar A, Roberts M, Wood S, Healy H, Kassianos A, Mallett A
Front Oncol
. 2022 Oct;
12:943583.
PMID: 36313721
Clear cell renal cell carcinoma (ccRCC) is globally the most prevalent renal cancer. The cells of origin in ccRCC have been identified as proximal tubular epithelial cells (PTEC); however, the...
10.
Tunbridge M, Grivei A, Kassianos A, Davis H, Stewart A, Healy H, et al.
Nephrology (Carlton)
. 2022 Sep;
27(11):908-909.
PMID: 36113860
No abstract available.